Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213791 | 1.00 | LMNA (0.69) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL16262847 | 0.89 | LMNA (0.54) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL16262843 | 0.89 | LMNA (0.54) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL5058364 | 0.88 | MAPT (0.71) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL16262196 | 0.87 | SIRT6 (0.54) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL16262194 | 0.87 | SIRT6 (0.54) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL1842221 | 0.86 | MAPT (0.67) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL2552086 | 0.84 | MAPT (0.66) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL23293980 | 0.84 | SIRT6 (0.54) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL17958719 | 0.83 | SMN1; SMN2 (0.54) | LMNAMAPTSIRT6ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2020123855-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2020-06-18 | — | — | WO | disclosed |
| CN-102933557-B | Radiation protection immunomodulator compounds and method | 彼得·麦卡勒姆癌症研究所 | 2016-08-03 | — | — | CN | disclosed |
| CN-102933557-A | Radioprotector compounds and methods | PETER MACCALLUM CANCER INST | 2013-02-13 | — | — | CN | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-20030149020-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030149019-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149020-A1 | New compounds | GPR119, SULT2A1, NAT1 | LMNA 3478/4885MAPT 2577/4885SIRT6 757/4885 |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | LMNA 4821/4885MAPT 2138/4885SIRT6 3316/4885 |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | LMNA 1751/4885MAPT 4083/4885SIRT6 117/4885 |
| US-20030149019-A1 | New compounds | GPR119, SULT2A1, NAT1 | LMNA 3478/4885MAPT 2577/4885SIRT6 757/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | LMNA 1751/4885MAPT 4083/4885SIRT6 117/4885 |
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | LMNA 3475/4885MAPT 2697/4885SIRT6 678/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | LMNA 3475/4885MAPT 2697/4885SIRT6 678/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | LMNA 3475/4885MAPT 2697/4885SIRT6 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.